Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | DHODH | Q02127 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13398657 | 0.84 | LCK (0.48) | LCK | |
| SCHEMBL1715500 | 0.83 | PTGER1 (0.43) | LCK | |
| SCHEMBL1715610 | 0.82 | ADORA2A (0.51) | PTPN1LCKSCD | |
| SCHEMBL5767790 | 0.81 | MEN1 (0.60) | — | |
| SCHEMBL27774525 | 0.80 | DHODH (0.53) | PTPN1NR1H4MRGPRX4NR4A2DHODH | |
| SCHEMBL8282581 | 0.76 | PTGER1 (0.40) | LCKAURKARPS6KB1 | |
| SCHEMBL2953087 | 0.76 | GAA (0.41) | LCK | |
| SCHEMBL19974144 | 0.75 | GAA (0.59) | LCK | |
| SCHEMBL19974156 | 0.75 | LCK (0.47) | LCK | |
| SCHEMBL22920172 | 0.75 | PDK1 (0.65) | NR1H4PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759377-B2 | Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-7371770-B2 | Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors | SANOFIAVENTIS (FR) | 2008-05-13 | — | — | US | disclosed |
| US-20060293366-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | APP, BACE1, ATG4A | PTPN1 4167/4885NR1H4 3340/4885MRGPRX4 2425/4885 |
| US-20060293366-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | APP, BACE1, ATG4A | PTPN1 4167/4885NR1H4 3340/4885MRGPRX4 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.